Hematologic cancers begin in blood-forming tissues such as the bone marrow or in the cells of the immune system. Another name for hematologic cancer is blood cancer. Types of blood cancer include:

Lymphoma

  • Hodgkin Lymphoma
  • Non-Hodgkin Lymphoma including:
    • Burkitt Lymphoma
    • Diffuse Large B-cell 
Lymphoma (DLBCL)
    • Follicular Lymphoma (FL)
    • Mantle Cell Lymphoma (MCL)
    • Marginal Zone Lymphoma (MZL)
    • Richter’s Transformation (RT)
    • Small Lymphocytic Lymphoma (SLL)
    • Waldenstrom’s 
Macroglobulinemia (WM)

Leukemia

  • Acute Myeloid Leukemia (AML)
  • Chronic Lymphocytic Leukemia (CLL)

Other blood cancers

  • Essential Thrombocythemia
  • Multiple Myeloma

Current clinical trials for blood cancers explore investigational medications including: pembrolizumab, bomedemstat, vibostolimab, nemtabrutinib, zilovertamab vedotin, or favezelimab.

MOCT-Web-TA-Image-Hematologic-2_card-size

Lymphoma clinical trials

Lymphoma is the most common type of blood cancer.
View lymphoma trials
MOCT-Web-TA-Image-Hematologic-1_card-size

Leukemia clinical trials

Leukemia is a cancer of the blood cells, and typically starts in blood-forming tissue, such as bone marrow.
View leukemia trials

Additional blood cancer clinical trials

Outside of the two most common blood cancer categories, leukemia and lymphoma, there are multiple other types of blood cancers that we research.
View additional blood cancer trials

There is a lot to consider when deciding whether to participate in a clinical trial. Any clinical trial includes risks, which the study doctor will review with you. Make sure you understand the risks before participating

GettyImages-1211642777

Resources for patients

For help understanding clinical trial listings and for other resources, visit our Patient Resources section.
Patient Resources
GettyImages-1211642948

About clinical trials

Learn what clinical trials are, how they work, and if you may be eligible to participate.
Learn more